Rab Prinjha

Curve Therapeutics has appointed Rab Prinjha as Chief R&D Officer

Curve Therapeutics has appointed Rab Prinjha as Chief Research and Development (R&D) Officer.

Rab is a proven R&D leader with a more than 20-year track record of success leading drug discovery programmes and collaborations pioneering research across immunology, oncology, neuroscience and epigenetics using small molecule, nucleic acid and biologic modalities.

He joins from GSK where he was Head of the Immunology Research Unit and Immunology Network sponsor and led the team reshaping and focusing the immunology research portfolio. Under his leadership this team delivered over 15 clinical candidates and over 30 new targets.

Curve’s mission is to improve patient outcomes by discovering innovative drugs that address the most challenging and complex disease targets.

Rab will be responsible for the therapeutic portfolio strategy to advance the Company’s growing pipeline of first-in-class assets, including a dual HIF-1/HIF-2 inhibitor and an inhibitor of ATIC homodimerisation.

He will also leverage his expertise in oncology, neuroscience, immunology and epigenetics to further enhance target selection and validation using Curve’s revolutionary, disease agnostic Microcycle discovery platform.

Simon Kerry, Chief Executive Officer of Curve Therapeutics, said: “Rab is the latest addition to the truly world-class leadership team we are assembling at Curve; his skill set, experience and passion align with our mission to successfully drug complex and challenging disease targets and develop life-changing drugs for patients.”